Department of Hematology

Hematology Home >

Faculty

Bruce Joseph Giantonio, M.D.

Associate Professor of Medicine at the Hospital of the University of Pennsylvania and the Presbyterian Medical Center of Philadelphia

Department: Medicine

Contact information

16 Penn Tower
3400 Spruce Street
Philadelphia, PA 19104

Office: 215-662-6318
Fax: 215-349-5326

Email:
bruceg@mail.med.upenn.edu

Education:

St. Michael’s College, 1979.
BA (Biology)
Hofstra University, 1980.
MS (Physiology/Biophysics)
Georgetown University, 1983.
M.D.
Georgetown University, 1987.

Post-Graduate Training
Intern in Medicine, Medical Center Hospital of Vermont, University of Vermont School Of Medicine, Burlington, Vt., 1987-1988.
Resident in Internal Medicine, Medical Center Hospital of Vermont, 1988-1990.
Clinical Fellow in Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pa., 1990-1991.
Research Fellow in Medical Oncology, Fox Chase Cancer Center, 1991-1993.

Certifications
American Board of Internal Medicine, 1991.
American Board of Internal Medicine, Medical Oncology, 1992.
American Board of Internal Medicine, Recertification, 2002.
American Board of Internal Medicine, Medical Oncology Recertification., 2002.

Permanent link

> School of Medicine > Faculty > Details

Description of Research Expertise

Clinical Investigation of targeted agents in gastrointestinal malignancies

Description of Clinical Expertise

Treatment of all gastrointestinal malignancies

Selected Publications

Flaherty K.T., Stevenson, J.P., Gallagher, M., Giantonio, B., Algazy, K.M., Sun, W., Haller, D. G., O’Dwyer, P.J: Dose escalation study of tezacitabine in combination with cisplatin in patients with advanced cancer. Cancer 97(8): 1985-1990, 2003.

Giantonio, B.J., Levy, D., O’Dwyer, P.J., Meropol, N.J., Catalano, P.J., Benson, A.B.: Bevacizumab (anti-VEGF) plus IFL (irinotecan, fluorouracil, leucovorin) as front-line therapy for advanced colorectal cancer (advCRC): results from the Eastern Cooperative Oncology Group (ECOG) Study E2200. Proc. Am. Soc. Clin. Oncol. 22: 255 (abs1024), 2003.

Benson, A.B., Catalano, P.J., Meropol, N.J., O’Dwyer, P.J., Giantonio, B.J: Bevacizumab (anti-VEGF) plus FOLFOX4 in previously treated advanced colorectal cancer (advCRC): an interim toxicity analysis of the Eastern Cooperative Oncology Group (ECOG) study E3200. Proc. Am. Soc. Clin. Oncol 22: 204 (abs975), 2003.

Gray, R., Giantonio, B.J, O’Dwyer, P.J., Sandler, A., Miller, K., Comis, R.L: The safety of adding angiogenesis inhibition into treatment for colorectal, breast, and lung cancer: the Eastern Cooperative Oncology Group’s (ECOG) experience with bevacizumab (anti-VEGF). Proc. Am. Soc. Clin. Oncol. 22: 206 (abs825), 2003.

Sun, W., Stevenson, J.P., Gallo, J.M., Redlinger, M., Haller, D., Algazy, K, Giantonio, B., Alila, H., O’Dwyer, P.J: Phase I and pharmacokinetic trial of the proapoptotic sulindac analog CP-461 in patients with advanced cancer. Clin Cancer Res 8(10): 3100-3104, 2002.

Giantonio, B.J., Levy, D., Catalano, P.J., O’Dwyer, P.J., Benson, A.B: Incorporating angiogenesis inhibition with bevacizumab (anti-VEGF) into frontline chemotherapy with irinotecan (CPT-11), fluorouracil and leucovorin (FU/LV) for advanced colorectal cancer: a toxicity analysis of ECOG study E2200. Proc. Am. Soc. Clin. Oncol. 21: 126a (abs503), 2002.

O’Dwyer P.J., Stevenson J.P., Haller D.G., Rotman N., Giantonio B.J: Follow-up of stage B and C colorectal cancer in the United States and France. Semin Oncol 28: 45-49, 2001.

Giantonio B.J., Hochster H., Blum R., Wiernik P.H., Hudes G.H., Kirkwood J., Trump D., Oken M.M: Toxicity and response evaluation of the interferon inducer poly ICLC administered at low dose in advanced renal carcinoma and relapsed or refractory lymphoma: A report of two clinical trials of the Eastern Cooperative Oncology Group. Invest New Drugs 19: 89-92, 2001.

Sun W., Stevenson J.P., Gallagher M., Giantonio B.J., Algazy K., Haller D., Vaughn D., Raskay B. J., O’Dwyer P.J: A Phase I trial of topotecan and gemcitabine administered weekly for 3 consecutive weeks to patients with advanced tumors. Cancer 92: 414-419, 2001.

Malone T., Catalano P.J., O’Dwyer P.J., Giantonio B: High Rate of Consent to Bank Biological Samples for Future Research: The Eastern Cooperative Oncology Group Experience. J Natl Cancer Inst 94(10): 769-771, 2001.